AIC
CRNX icon

Ameritas Investment Company’s Crinetics Pharmaceuticals CRNX Stock Holding History

Ameritas Investment Company’s Portfolio CRNX Stock Details CRNX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q2 		– Sell
-300
Closed -$4.58K – 999
2021
Q1 		$4.58K Buy
+300
New +$4.65K ﹤0.01% 1729
2020
Q2 		– Sell
-300
Closed -$4K – 548
2020
Q1 		$4K Buy
+300
New +$6.15K ﹤0.01% 1422
2019
Q4 		– Sell
-160
Closed -$3K – 971
2019
Q3 		$3K Buy
+160
New +$3.11K ﹤0.01% 1369
2019
Q2 		– Sell
-160
Closed -$4K – 358
2019
Q1 		$4K Buy
+160
New +$3.93K ﹤0.01% 774

Other funds holding CRNX

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
DCM
Driehaus Capital Management Chicago, Illinois $13.6B AUM 173.98% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
NLVP
New Leaf Venture Partners New York $43M AUM 25.55% 1-Year Est. Return
VC
Vivo Capital Palo Alto, California $1.2B AUM 911.44% 1-Year Est. Return
BCLSI
Bain Capital Life Sciences Investors Boston, Massachusetts $1.11B AUM 171.34% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
5VM
5AM Venture Management San Francisco, California $360M AUM 345.76% 1-Year Est. Return

Ameritas Investment Company's CRNX Position: Q2 2021 in Review

Ameritas Investment Company sold out of Crinetics Pharmaceuticals (CRNX) in Q2 2021, closing a stake of 300 shares — an estimated $4.58K sold.

Ameritas Investment Company first reported a position in CRNX in Q1 2019 and held it in 4 quarters. The position peaked at $4.58K in Q1 2021. 83 funds tracked by Wall St. Rank hold CRNX as of Q2 2021.

  • Ameritas Investment Company reported no remaining Crinetics Pharmaceuticals position as of Q2 2021 after selling out during the quarter.
  • Ameritas Investment Company sold 300 Crinetics Pharmaceuticals shares in Q2 2021, an estimated $4.58K.
  • Ameritas Investment Company first reported a position in Crinetics Pharmaceuticals in Q1 2019 and held it in 4 quarters.
  • Ameritas Investment Company's Crinetics Pharmaceuticals position peaked at $4.58K in Q1 2021.
  • 83 funds tracked by Wall St. Rank held Crinetics Pharmaceuticals as of Q2 2021.

Based on Ameritas Investment Company's 13F filing for Q2 2021, filed 16 Aug 2021.